S. 4994, Corporate Tax Subsidy for Pharma/Medical Device Manufacturing. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.

What it does

This bill creates three new federal tax credits to incentivize domestic manufacturing of critical medical supplies, drugs, and devices. Companies that manufacture specified medical products in the U.S. receive a 10.5% credit on qualified manufacturing income (capped at 50% of wages paid), a 30% equipment credit for advanced manufacturing machinery (phasing down to 0% after 2032), and a 30% credit for pollution-control equipment to meet EPA standards. The bill benefits pharmaceutical, biotech, and medical device manufacturers by reducing their tax burden in exchange for onshore production.

The analysis names Pharmaceutical manufacturers (large-cap and mid-cap) — and 4 more groups — among the beneficiaries.

The trade-off

The bill does not mandate price reductions or supply commitments; companies receive tax credits simply for manufacturing domestically, with no guarantee of lower drug prices or improved availability for patients.

The analysis put a high warning level on this bill. Transparency scores 35%, and the analysis found no provisions unrelated to the bill's subject.

Who is behind it

Filed by Marsha Blackburn.